BioMedNewsBreaks Archive - BioMedWire (BMW)

MondaySep 09, 2024 1:09 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is spotlighted in this week’s episode of The BioMedWire Podcast. During the episode, Scinai Immunotherapeutics CEO Amir Reichman talks with host Carmel Fisher about SCNI’s business model as well as entities and experts the company works closely with. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. “In the end, we went for a derisking strategy where our molecular targets are molecular…

MondaySep 09, 2024 12:42 pm

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox

Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, is announcing data presented at an immunology symposium at the University of Alberta. Titled “Using Synthetic Biology to Battle Mpox,” the presentation detailed positive preclinical data on Tonix’s vaccine platform, led by TNX-801, an attenuated live-virus vaccine based on synthesized horsepox, for preventing mpox (formerly known as monkeypox). TNX-801 has been shown to provide animals with single-dose immune protection against a lethal challenge with clade I monkeypox. New data also shows that TNX-801 has better tolerability than 20th century vaccinia live-virus vaccines in…

MondaySep 09, 2024 9:43 am

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is focused on beginning Proof of Concept preclinical studies to evaluate its lead therapeutic TCB 008 for treatment in monkey pox. According to the announcement, TCBP will partner with a leading infectious disease center or university associated with a similar organization to advance the studies as quickly as possible. “There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells,” said TC BioPharm CEO Bryan Kobel in the press…

ThursdaySep 05, 2024 12:58 pm

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TC BioPharm (NASDAQ: TCBP), a clinical stage biotechnology company developing allogeneic gamma-delta T cell therapies for cancer and other indications, today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York City. According to the announcement, Bryan Kobel, CEO of TC BioPharm, will deliver a presentation providing an overview of the company’s business. To view the full press release, visit https://ibn.fm/17ZaO About TC BioPharm Holdings PLC TC BioPharm is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the…

ThursdaySep 05, 2024 10:49 am

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced participation at the H.C. Wainwright 26th Annual Global Investment Conference. The conference, held virtually and in person, is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel in New York City. According to the announcement, Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, will deliver a 30-minute company presentation on Tuesday, September 10, 2024, at 8 a.m. ET. Later that day, at 2 p.m. ET., Dr. Maccecchini will take part in…

WednesdaySep 04, 2024 3:33 pm

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, is developing TNX-102 SL, a new nonaddictive treatment for fibromyalgia, the prototypic nociplastic pain syndrome. According to a recent post, research into the causes and nature of pain is increasing; the post observed that there were more than 400 scientific presentations at the 2024 Word Congress on Pain, which was held Aug. 6–9, 2024, and was sponsored by the International Association for the Study of Pain. The article noted there different types of pain have been identified: nociceptive pain, neuropathic pain and nociplastic pain.…

WednesdaySep 04, 2024 3:25 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. The event is slated for Sept. 9–11, 2024, in New York. According to the announcement, CEO John Climaco will present at the event; his presentation will be available as an on-demand video webcast beginning Sept. 9 at 7 a.m. ET. Climaco will also be available to participate in one-on-one meetings. To view the on-demand webcast, visit https://ibn.fm/gaP8o To view the full…

WednesdaySep 04, 2024 2:18 pm

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M

Oragenics (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, has entered into a placement agency agreement. The agreement is for the purchase and sale of 8,106,584 shares of its common stock (or prefunded warrants in lieu thereof). The shares are offered at $0.55 per share (or $0.549 per prefunded warrant in lieu thereof). According to the announcement, the offering is expected to close on or about Sept. 5, 2024. Gross proceeds of the offering, which will be subject to customary closing conditions, are estimated to be approximately $4.45 million before deduction of…

WednesdaySep 04, 2024 1:55 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, is reporting its Q2 2024 financial results for the period ending July 31, 2024. According to the report, the company ended the quarter in a strong cash position, reinforcing its ability to advance the development of its lead product, AVERSA(TM) Fentanyl, with a New Drug Application (“NDA”) submission planned for the first half of 2025. The report showed Nutriband with cash reserves of $6.75 million, supporting the company's ongoing development and commercialization efforts for AVERSA Fentanyl; total assets are valued at $13.63 million, with stockholders' equity amounting to $12.5 million. The…

WednesdaySep 04, 2024 1:39 pm

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has dosed five new patients in the ongoing ACHIEVE phase 2b trial in the United Kingdom. According to the announcement, that brings the total number of patients dosed to six; five patients have received a second dose and two patients have received a third dose. The announcement noted that there are four possible doses at the higher dose level, with each 5mL dose containing up to 230 million gamma delta T cells. New patients will continue to be identified, screened and enrolled into…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

BioMedNewsBreaks

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Plans Preclinical Studies for Treatment of Monkey Pox

BioMedNewsBreaks — TC BioPharm Holdings PLC (NASDAQ: TCBP) CEO to Present at the H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Slated to Present at H.C. Wainwright 26th Annual Global Investment Conference

BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update

BioMedNewsBreaks — TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search